Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

2004 • 4,872 citations

T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions

1998 • 2,615 citations

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

1998 • 2,373 citations

Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes

1998 • 2,078 citations

Immunologic tolerance maintained by CD25⁺ CD4⁺ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance

2001 • 1,515 citations

Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity

1999 • 1,475 citations

Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

1999 • 1,066 citations

Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

2005 • 878 citations

Indirect activation of naïve CD4+ T cells by dendritic cell–derived exosomes

2002 • 877 citations

CD4⁺CD25⁺ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

2004 • 854 citations

CD25+ CD4+ T Cells, Expanded with Dendritic Cells Presenting a Single Autoantigenic Peptide, Suppress Autoimmune Diabetes

2004 • 741 citations

A fresh look at tumor immunosurveillance and immunotherapy

2001 • 723 citations

Production and characterization of clinical grade exosomes derived from dendritic cells

2002 • 662 citations

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

1982 • 640 citations

Human Plasmacytoid Dendritic Cells Activated by CpG Oligodeoxynucleotides Induce the Generation of CD4+CD25+ Regulatory T Cells

2004 • 629 citations

Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells

2004 • 541 citations

CD4+CD25+ T Cells Regulate Virus-specific Primary and Memory CD8+ T Cell Responses

2003 • 531 citations

HLA-A2.1–restricted Education and Cytolytic Activity of CD8+ T Lymphocytes from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2Db β2m Double Knockout Mice

1997 • 486 citations

Exosomes as Potent Cell-Free Peptide-Based Vaccine. I. Dendritic Cell-Derived Exosomes Transfer Functional MHC Class I/Peptide Complexes to Dendritic Cells

2004 • 468 citations

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

2001 • 454 citations

Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses.

1975 • 434 citations

Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens

2002 • 289 citations

CD25+CD4+ Cells Contribute to Th2 Polarization during Helminth Infection by Suppressing Th1 Response Development

2004 • 265 citations

Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection

2004 • 262 citations

CD4+ CD25+ Regulatory T Cells Control T Helper Cell Type 1 Responses to Foreign Antigens Induced by Mature Dendritic Cells In Vivo

2003 • 230 citations

Regulatory CD4+CD25+ T Cells Restrict Memory CD8+ T Cell Responses

2002 • 209 citations

Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity

1974 • 209 citations

Enhancement of delayed hypersensitivity by depletion of suppressor T cells with cyclophosphamide in mice

1976 • 198 citations

CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination

2003 • 192 citations

Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.

1988 • 168 citations

Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.

1989 • 149 citations

Tumor Rejection by Disturbing Tumor Stroma Cell Interactions

2001 • 147 citations

CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens.

2003 • 139 citations

Enhancement of Dinitrochlorobenzene (DNCB) Contact Sensitization by Cyclophosphamide in the Guinea Pig**From the Department of Dermatology, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19104.

1967 • 133 citations

Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden.

1988 • 119 citations

Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.

1981 • 100 citations

Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer

1998 • 94 citations

Effects of anticancer drugs on the immune system in humans.

1989 • 86 citations

Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma

2004 • 79 citations

A cautionary note on experimental artefacts induced by fetal calf serum in a viral model of pulmonary eosinophilia

2002 • 68 citations

Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL

2000 • 45 citations

Progression to Islet Destruction in a Cyclophosphamide-Induced Transgenic Model

2004 • 44 citations

Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy.

1981 • 38 citations